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Visual impairment is common in people living with dementia and regular ophthalmological exams may 
improve their quality of life. We evaluated visual function in a cohort of elderly individuals and analyzed 
its association with their degree of cognitive impairment. participants underwent neurological and 
neuropsychological exams, neuro-ophthalmological assessment (visual acuity, intraocular pressure, 
rates of past ophthalmological pathologies, use of ocular correction, treatments and surgeries) and 
optical coherence tomography (OCT) scan. We analyzed differences in ophthalmological characteristics 
among diagnostic groups. The final sample of 1746 study participants aged ≥ 50 comprised 229 
individuals with Subjective Cognitive Decline (SCD), 695 with mild cognitive impairment (MCI) and 
833 with Dementia (Alzheimer disease: n = 660; vascular dementia: n = 92, Lewy body dementia: 
n = 34; frontotemporal dementia: n = 19 and other: n = 28). Age, gender and education were used 
as covariates. patients with Dementia, compared to those with sCD and MCI, presented worse 
visual acuity (p < 0.001), used less visual correction (p = 0.02 and p < 0.001, respectively) and fewer 
ophthalmological treatments (p = 0.004 and p < 0.001, respectively) and underwent fewer ocular 
surgeries (p = 0.009 and p < 0.001, respectively). OCT image quality worsened in parallel to cognitive 
decline (Dementia vs sCD: p = 0.008; Dementia vs MCI: p < 0.001). No group differences in past 
ophthalmological disorders or abnormal OCT findings were detected. Efforts should be made to ensure 
dementia patients undergo regular ophthalmological assessments to correct their visual function in 
order to improve their quality of life.
Alzheimer’s Disease (AD), the leading cause of dementia in the elderly, is a neurodegenerative condition that 
irreversibly impairs cognition1. AD symptoms progressively develop over time and include memory loss, impair-
ment of judgment, disorientation, personality changes and emotional disturbances2. Visual abnormalities are also 
common in AD, leading to falls, confusion and difficulty with activities of daily living. In combination with visual 
hallucinations, poor vision can affect an individual’s autonomy and quality of life3. Large population studies have 
identified a higher prevalence of age-related visual problems among elderly people with dementia compared to 
the general population4. The burden of both visual impairment and cognitive decline is expected to rise in the 
near future due to the increase in life expectancy5,6.
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AD-related neuropathological lesions have been described in all parts of the visual system7–10 and result in a 
variety of signs and symptoms. These lesions include deposition of β-amyloid plaques in the lens7, reduction in 
the number of retinal ganglion cells and thinning of the peripapillary retinal nerve fiber layer (RNFL)8,11, optic 
disc pallor, atrophy and cupping12,13, reduction of axons in the optic nerve14,15, accumulation of lipofucsin in the 
lateral geniculate nucleus3, loss of pyramidal cells in the visual cortex9,16, and presence of numerous cored senile 
plaques but few neurofibrillary tangles in the visual cortex10,16.
Common visual symptoms reported in AD comprise diminished color contrast sensitivity17, visual field 
defects18, delayed saccadic eye movements and slow pursuit movements19, complex visual deficits such as poor 
understanding of written words (impairing reading abilities)20, difficulties in object and shape recognition20,21 and 
problems finding objects22. Additionally, 20% of AD patients experience visual hallucinations, especially those 
with impaired vision and more severe cognitive decline23. Posterior cortical atrophy (PCA) is a neurodegenerative 
condition that affects the visual-processing pathways and is mostly associated with underlying AD pathology 
primarily in the visual association areas24. PCA manifests with visual symptoms such as difficulties in reading 
and driving, object ataxia, oculomotor apraxia, simultanagnosia, left hemineglect, topographical disorientation, 
agraphia, acalculia, visual agnosia and prosopagnosia, among others, and it can be severely disabling as affected 
patients behave like a blind person. Individuals suffering from other types of dementia different from AD may 
also exhibit significant visual problems. Dementia with Lewy bodies (DLB) is the second most frequent type of 
neurodegenerative dementia and is characterized by parkinsonism, cognitive fluctuations and vivid visual hallu-
cinations co-occurring with the onset of cognitive decline25. Impairments in multiple visual domains have been 
described in DLB, such as visual construction, object and space-motion perception, line orientation perception 
and saccadic eye movements. In post-stroke vascular dementia, up to 30% of patients experience visual impair-
ment26. Homonymous hemianopia (especially in occipital strokes) is the most reported symptom, but neglect, 
diplopia, ptosis, anisocoria and nystagmus have also been described. Charles-Bonnet syndrome is a common 
cause of visual hallucinations secondary to poor vision in elderly population27.
As dementia evolves, patients become less capable of describing and complaining about their visual prob-
lems28. Thus, it is essential to perform periodical ophthalmological screenings to assess their visual acuity, rule 
out common age-related eye pathologies such as open-angle glaucoma, age-related macular degeneration (AMD) 
and dry eye syndrome and offer appropriate vision correction or treatment if available (e.g. earlier cataract extrac-
tion), which can potentially lead to improvement of patients’ functional state.
We aimed to assess visual function and ophthalmological care received in a cohort of older adults who 
were attending a Memory Clinic due to cognitive decline and to determine whether their degree of cognitive 
impairment influenced the presence, prior detection and correction/treatment of common ocular patholo-
gies. Evaluation was carried out by performing a neuro-ophthalmological exam and an Optical Coherence 
Tomography (OCT) scan.
Methods
study subjects. Fundació ACE is a non-profit organization located in Barcelona, Spain that was declared 
a welfare institution by the Generalitat of Catalonia in 1995. The present study derives from the Neuro-
Ophthalmology Research At Fundació ACE (NORFACE) cohort, which was founded in 2014 to search for retinal 
biomarkers of AD and examine the relationship between retinal changes and different types of neurodegenerative 
disorders29. Consecutive patients evaluated due to cognitive decline at Fundació ACE between January 2017 and 
March 2018 were enrolled in the present study. Participants were recruited from three sources: 1) the Memory 
Clinic, an outpatient diagnostic unit for patients with cognitive decline that has an agreement with the Catalan 
Public Health System, 2) Fundació ACE’s Open House Initiative30, a corporate social responsibility program that 
assesses for free the cognitive status of individuals from the community without the need of a physician’s referral, 
and 3) Fundació ACE Healthy Brain Initiative (FACEHBI)31, a research study with the goal of identifying biomark-
ers of preclinical AD in individuals with Subjective Cognitive Decline (SCD). Inclusion criteria were: age ≥ 50-yo, 
presence of a consensus-based clinical diagnosis about the participants’ cognitive status and ability to complete 
the full ophthalmological exam and OCT scan (excluding those patients with severe dementia stages, equivalent 
to a Global Deteriorating Scale [GDS]32 score > 6).
Clinical diagnostic groups. Study participants completed neurological, neuropsychological and social 
evaluations at Fundació ACE. For each individual, a consensus-based diagnosis about his/her cognitive status 
(Dementia vs mild cognitive impairment [MCI] vs subjective cognitive decline [SCD]) was reached at the time of 
the study recruitment by a multidisciplinary team of professionals that included neurologists, neuropsychologists 
and social workers33. Cognitive assessment consisted of the Spanish version of the Mini-Mental State Examination 
(MMSE)34,35, the memory part of the Spanish version of the 7 Minutes test36, the Hachinski Ischemic Scale37, the 
Spanish version of the Neuropsychiatric Inventory Questionnaire (NPI-Q)38, the GDS32, the Clinical Dementia 
Rating Score (CDR)39, the Blessed Dementia Scale40 and a comprehensive neuropsychological battery of Fundació 
ACE (NBACE)41,42. Demographical information collected included age, gender and years of education.
Dementia was defined according to the DSM-V criteria43. MCI was defined using Petersen’s criteria44. SCD 
refers to the perception of memory or other cognitive problems without impairment on standardized cogni-
tive tests45. Specifically, individuals with SCD had a CDR39 of 0, a preserved performance (score ≥ 27) on the 
MMSE34,35, a score of ≥8 on the Spanish Modified Questionnaire of Memory Failures in Everyday (MFE-30)46, 
and a strictly normal performance in the NBACE41,42.
Neuro-ophthalmological evaluation. Study participants underwent a complete neuro-ophthalmological 
evaluation in parallel to the cognitive evaluation (usually the same day of the initial neurological assessment). The 
whole visit was performed by an optometrist and was completed in 20 mins. In order to undergo the exam, subjects 
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had to be able to cooperate, obey simple instructions and sit still for a few minutes. The evaluation comprised: 1) 
review of past ophthalmological diseases, treatments and surgeries, 2) monocular visual acuity assessment with the 
participants wearing their habitual correction for refractive error using a pinhole occluder and the Early Treatment 
of Diabetic Retinopathy Study (ETDRS) chart47,48, 3) intraocular pressure (IOP) measurement by Icare tonometry49, 
and 4) swept source (SS) OCT scan. The visual acuity assessment was done the same way for all participants, regard-
less of their cognitive status and level of cooperation. Reduced visual acuity was defined as a standard LogMAR 
fraction scale ≤ 20/50 at 20 ft (equivalent to a fraction scale of 6/15 at 6 m and a decimal scale of 0.4) according to 
the Snellen scale50, which is in line with the North American guidelines of visual loss51. High IOP was defined as 
≥24 mmHg using Icare Tonometry49. All assessments were carried out by a single optometrist and reviewed by a 
single ophthalmologist. Before beginning the study, the ophthalmologist trained the optometrist in the evaluation of 
OCT images, with the goal to differentiate normal images from abnormal findings. The ophthalmologist reviewed 
the ophthalmological history, ocular exam findings and OCT images from those cases in which OCT images were 
considered abnormal by the optometrist and came up with a diagnosis if appropriate. Of note, the diagnoses of 
dry and wet AMD were based on the Age-Macular Degeneration Preferred Practice Patterns guidelines from the 
American Academy of Ophthalmology (2015)52, which uses the classification of the Age-Related Eye Disease Study53 
and a more recent classification to define the early and intermediate stages of AMD54. The glaucoma category was 
established based on the image of the head of the optic nerve (ONH), ONH OCT findings and Icare IOP measure-
ments. If a participant presented with what is commonly called a “suspicious papilla”, an IOP > 24 mmHg, and signs 
of thinning of the RNFL in the OCT, the case was assigned a label of “glaucoma” based on OCT-findings. No anterior 
chamber OCT imaging was available. The ophthalmologist and neurologists were blind to each other’s diagnosis.
optical coherence tomography. Participants were imaged with a DRI OCT Triton - Swept Source 
(SS) OCT, software v.1.22.1 (Topcon Co. Tokyo, Japan). The OCT exam was completed in about 5–10 minutes. 
Both eyes were scanned separately. No pupil dilation was required. The device used to capture OCT integrates 
a high-quality retinograph, which acquires a color image of the fundus at the same time that OCT structural 
and vascular measures are obtained. These images were used as support when analyzing the cases. Retinal layer 
segmentation from the macular and peripapillary regions was performed using the Topcon Advanced Boundary 
Segmentation TM (TABS) algorithm as part of the Fast Map software55 (data not shown).
ethical considerations. This study and its informed consent were approved by the ethics committees of the 
Hospital Clínic i Provincial de Barcelona and the Hospital Universitari Vall d’Hebron in Barcelona, Spain, in accord-
ance with Spanish biomedical laws (Law 14/2007, July 3rd, about biomedical research; Royal Decree 1716/2011, 
November 18th) and followed the recommendations of the Declaration of Helsinki. All participants signed the 
study informed consent (for those with moderate dementia stages, the informed consent was signed by their legal 
representative or family member).
statistical analysis. Data processing and analysis were conducted using SPSS statistical software v. 20. Alpha 
level was set at 0.05. Frequency analysis and measures of central tendency and dispersion were used to describe 
the study variables. Bootstrap was used to resample the cohort in order to obtain the 95% confidence inter-
val (CI) for each variable. Demographic data differences among diagnostic groups (SCD vs MCI vs Dementia) 
were assessed with an ANOVA test for quantitative variables (age, years of education and MMSE scores) and a 
Chi-Square test for qualitative variables (gender). A Multinomial Logistic Regression (MLR) model including age, 
gender and years of education as co-variates was used to analyze the differences in ophthalmological pathologies 
(history of glaucoma and AMD, use of corrective lenses, past ocular surgeries and current ophthalmological 
treatment), visual exam (low visual acuity and high IOP) and OCT scan findings (suboptimal OCT image quality, 
abnormal OCT findings and newly detected ophthalmologic pathology) among the three diagnostic groups. We 
performed a similar MLR model within the Dementia cohort (n = 684) to analyze differences in visual acuity 
across GDS sub-groups, including age, gender and years of education as co-variates. Additionally, we performed a 
Linear Regression Analysis adjusted by age, gender and years of education within the Dementia cohort to explore 
the relationship between MMSE scores and visual acuity.
Results
Demographical characteristics of the cohort. 1813 individuals were assessed between January 2017 
and March 2018, had a consensus-based clinical diagnosis and underwent ophthalmological exam and OCT scan. 
Of those, we excluded 22 individuals due to age < 50 and 45 due to incomplete ophthalmological exam and/or 
OCT scan. Detailed reasons for the exclusions are reported in Supplementary Table S1.
The final study cohort comprised 1746 individuals. Participants were sub-classified into 3 clinical groups 
according to their cognitive stage: SCD, MCI and Dementia. Due to the low number of cases observed in a few 
variables and in order to be able to run the appropriate statistical analysis, we simplified the dataset and dichoto-
mized the subcategories within each ophthalmological variable (present/absent or normal/abnormal). A descrip-
tion of the study sample used for statistical analysis is shown in Tables 1–3, while detailed information is shown 
in Supplementary Tables 2–4.
Demographic information of the cohort is displayed in Table 1. Mean age was 76.7 ± 9.17 years and 1149 par-
ticipants (65.8%) were female. 229 individuals (13.1%) were classified as SCD, 684 (38.2%) as MCI and 833 (47.7%) 
as Dementia. Within the Dementia group, 660 patients were diagnosed as AD56, 92 as vascular dementia57, 34 as 
Lewy body spectrum dementia25 19 as frontotemporal dementia (FTD)58, and 28 as other dementia types (data not 
shown). Within the Dementia group we employed the GDS32 to sub-classify patients into three categories: Mild 
(GDS 4, n = 498, 59.78%), Moderate (GDS 5, n = 294, 29.89%) and Moderate-Severe (GDS 6, n = 41, 4.9%).
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We detected significant differences among diagnostic groups in terms of age (SCD 66.7 ± 7.7, MCI 74.2 ± 8.0, 
Dementia 81.4 ± 7.2; ANOVA p < 0.001), gender (females: SCD 149 (65.1%), MCI 422 (61.7%), Dementia 579 
(69.4%); ANOVA p = 0.01) and years of education (SCD 11.7 ± 3.7, MCI 7.3 ± 4.1, Dementia 5.9 ± 3.9; ANOVA 
p < 0.001, Table 1). Consequently age, gender and years of education were added as co-variates in the analyses. 
As expected, MMSE34,35 scores were significantly different among the diagnostic groups (SCD 29.2, MCI 26.0, 
Dementia 18.3; ANOVA p < 0.001; Table 1).
past ophthalmological history. Data from the participants’ past ophthalmological history are detailed in 
Tables 2 and 4 and Supplementary Table S2.
137 individuals (7.8%) had a previous diagnosis of open-angle glaucoma (13 (5.7%) with SCD, 60 (8.8%) with 
MCI and 64 (7.7%) with Dementia), while 71 participants (4.1%) had a previous diagnosis of age-related macular 
degeneration (AMD) (4 (1.7%) with SCD, 27 (3.9%) with MCI and 40 (4.8%) with Dementia). After adjusting for 
age, gender and years of education, no statistical differences in terms of open-angle glaucoma or AMD previous 
diagnosis were identified among diagnostic groups.
Most of the study participants (n = 1583, 90.7%) were currently using corrective lenses (218 (95.2%) with 
SCD, 643 (94%) with MCI and 722 (86.7%) with Dementia). After adjusting for age, gender and years of educa-
tion, data showed that patients with Dementia were less likely to be currently using lenses compared to individ-
uals with SCD (OR = 0.37, 95% CI = 0.17–0.84, p = 0.02) and MCI (OR = 0.46, 95% CI = 0.30–0.70, p < 0.001), 
while there were no significant differences between MCI and SCD participants.
728 participants (41.7%) had undergone ocular surgery (650 [89.29%] for cataract extraction, 18 [2.47%] 
due to glaucoma, 11 [1.51%] due to retinal detachment and 49 [6.73%] for other reasons: 59 (25.8%) with SCD, 
276 (40.4%) with MCI and 393 (47.2%) with Dementia). After adjusting for age, gender and years of education, 
patients in the Dementia group showed significant lower odds of having undergone ocular surgery compared to 
those with SCD (OR = 0.56, 95% CI = 0.37–0.87, p = 0.01) and MCI (OR = 0.60, 95% CI = 0.47–0.77, p < 0.001), 
while there were no significant differences between MCI and SCD groups.
538 participants (30.8%) were taking topical ophthalmological treatment (72 (31.4%) with SCD, 235 (34.4%) 
with MCI and 393 (27.7%) with Dementia). After adjusting for age, gender and years of education, the anal-
ysis showed that patients with Dementia were less likely to receive ophthalmological treatment than those in 
the SCD group (OR = 0.55, 95% CI = 0.37–0.82, p = 0.004) and the MCI group (OR = 0.59, 95% CI = 0.46–0.76, 
p < 0.001).
Ophthalmological exam findings. Data from the participants’ ophthalmological exam are detailed in 
Tables 3 and 5 and Supplementary Table S3.
453 participants (25.9%) suffered from low visual acuity as assessed by the ETDRS chart (14 (6.1%) with SCD, 
131 (19.2%) with MCI and 308 (37%) with Dementia). After adjusting for age, gender and years of education, 
data showed that patients with Dementia were almost 3.5-times more likely to present with reduced visual acuity 
compared to those in the SCD group (OR = 3.36, 95% CI = 1.77–6.39, p < 0.001) and over 1.5 times compared to 
those in the MCI group (OR = 1.61, 95% CI = 1.77–6.39, p < 0.001). Additionally, individuals with SCD had half 
the odds of presenting with reduced visual acuity than MCI patients (OR = 0.48, 95% CI = 0.25–0.90, p = 0.023). 
We analyzed differences in visual acuity within the Dementia cohort according to patients’ GDS status (GDS = 4: 
mild dementia, GDS = 5: moderate dementia and GDS = 6: moderate-severe dementia)32 (Supplementary 
Table S4). After adjusting for age, gender and years of education, data showed that patients with mild Dementia 
n
Whole cohort SCD MCI Dementia
p1746 229 684 866
Age, mean (SD) 76.7 ± 9.2 66.7 ± 7.7 74.2 ± 8.01 81.4 ± 7.2 <0.001*
Females, n (%) 1149 (65.8%) 149 (65.1%) 422 (61.7%) 579 (69.4%) 0.01*
Years of education, mean (SD) 7.2 (4.4) 11.69 (3.7) 7.27 (4.1) 5.9 (3.9) <0.001*
MMSE, mean (range) 22.9 (0–30) 29.2 (25–30) 26.0 (16–30) 18.7 (0–30) <0.001*
Table 1. Demographic characteristics of the study cohort. Statistical significance was set up at p < 0.05. A 
Chi-Square test was used to compare gender differences among groups. 1-factor ANOVA was used to compare 
age, years of education and MMSE scores differences among groups. MCI = mild cognitive impairment; 
MMSE = Mini-Mental State Examination; OCT = optical coherence tomography; SCD = subjective cognitive 
decline; SD = standard deviation.
Whole cohort (n = 1746) SCD (n = 229) MCI (n = 684) Dementia (n = 833)
Glaucoma, n (%, [95% CI]) 137 (7.8% [6.5–9.1]) 13 (5.7% [3.1–8.7]) 60 (8.8% [6.6–10.8]) 64 (7.7% [5.9–9.7])
AMD, n (%, [95% CI]) 71 (4.1% [3.2–5]) 4 (1.7% [0.4–3.5]) 27 (3.9% [2.5–5.4]) 40 (4.8% [3.5–6.2])
Corrective lenses, n (%, [95% CI]) 1583 (90.7% [89.3–92]) 218 (95.2% [92.1–97.8]) 643 (94% [92.1–97.8]) 722 (86.7% [84.2–89.1])
Past ocular surgeries, n (%, [95% CI]) 728 (41.7% [39.3–44.2]) 59 (25.8% [20.1–31.4]) 276 (40.4% [36.5–44]) 393 (47.2% [44.1–50.4])
Current ophthalmological treatment, n (%, [95% CI]) 538 (30.8% [28.5–31.8]) 72 (31.4% [25.3–37.6]) 235 (34.4% [31–38]) 231 (27.7% [24.7–30.7])
Table 2. Past ophthalmological history of the study cohort. AMD = age-related macular degeneration; 
CI = confidence interval; MCI = mild cognitive impairment; SCD = subjective cognitive decline.
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had 30% lower odds of presenting with reduced visual acuity compared to those with moderate Dementia 
(OR = 0.68; 95% CI = 0.50–0.93, p = 0.01). Patients with moderate-severe Dementia did not show significant 
differences in visual acuity compared to those with mild and moderate Dementia. Additionally, we explored the 
relationship within MMSE34 scores and visual acuity within the Dementia group adjusted by age, gender and 
years of education. Visual acuity had a statistical marginal effect on MMSE scores (p = 0.05), such as low visual 
acuity was associated to lower MMSE scores (data not shown).
Icare tonometry49 measurements showed that 110 participants (6.3%) had elevated IOP values (12 (5.2%) with 
SCD, 44 (6.4%) with MCI and 54 (6.5%) with Dementia). No statistical differences in terms of IOP were detected 
among diagnostic groups after adjusting for age, gender and years of education.
In 173 participants (9.9%) OCT scan images had suboptimal quality (1 (0.4%) with SCD, 42 (6.1%) with MCI 
and 130 (15.6%) with Dementia). After adjusting for age, gender and years of education, the analysis demon-
strated that patients with Dementia were at least 2-times more likely to show worse OCT image quality compared 
to SCD participants (OR = 14.95, 95% CI = 2.01–111.03, p < 0.008) and at least 1.4-times more likely compared 
to those with MCI (OR = 2.01, 95% CI = 1.36–2.98, p < 0.001). OCT image quality differences between SCD and 
MCI groups were borderline significant, with patients in the MCI group showing worse image quality than their 
peers with SCD (OR = 0.14, 95% CI = 0.02–1.00, p = 0.05).
In 315 participants (18%) OCT images were considered to be pathological (17 (7.4%) with SCD, 123 (18%) 
with MCI and 175 (21%) with Dementia) but no significant differences were detected among groups after adjust-
ing for age, gender and years of education. The most frequent OCT-based diagnosis was posterior pole defor-
mation due to posterior staphyloma/myopia magna (n = 70) followed by epiretinal membrane (n = 63), image 
Whole cohort (n = 1746) SCD (n = 229) MCI (n = 684) Dementia (n = 833)
Low visual acuity, n (%, [95% CI]) 453 (25.9% [24–27.9]) 14 (6.1% [3.5–9.2]) 131 (19.2% [15.9–22.1]) 308 (37% [33.9–40.3])
High IOP, n (%, [95% CI]) 110 (6.3% [5.2–7.4]) 12 (5.2% [2.6–7.9]) 44 (6.4% [4.7–8.3]) 54 (6.5% [4.8–8.3])
Suboptimal OCT image quality, n (%, [95% CI]) 173 (9.9% [8.6–11.3]) 1 (0.4% [0–1.3]) 42 (6.1% [4.2–7.9]) 130 (15.6% [13.1–18.1])
Abnormal OCT findings, n (%, [95% CI]) 315 (18% [16.2–19.8]) 17 (7.4% [4.4–10.9]) 123 (18% [15.2–20.8]) 175 (21% [18.2–23.8])
Newly detected ophthalmologic pathology, n (%, [95% CI]) 213 (12.2% [10.7–13.7]) 15 (6.6% [3.5–10.4]) 73 (10.7% [8.5–13]) 125 (15% [12.5–17.5])
Table 3. Ophthalmological exam and OCT findings of the study cohort. CI = confidence interval; 
IOP = intraocular pressure; MCI = mild cognitive impairment; OCT = optical coherence tomography; 
SCD = subjective cognitive decline.
OR (95% CI) p
Glaucoma
     Dementia vs SCD 0.90 (0.43–1.92) 0.79
     Dementia vs MCI 0.72 (0.48–1.07) 0.45
     SCD vs MCI 0.79 (0.39–1.60) 0.52
AMD
     Dementia vs SCD 0.97 (0.29–3.25) 0.96
     Dementia vs MCI 0.71 (0.41–1.23) 0.22
     SCD vs MCI 0.73 (0.23–2.38) 0.61
Corrective lenses
     Dementia vs SCD 0.37 (0.17–0.84) 0.02*
     Dementia vs MCI 0.46 (0.30–0.70) <0.001*
     SCD vs MCI 1.23 (0.56–2.70) 0.61
Past ocular surgeries
     Dementia vs SCD 0.56 (0.37–0.87) 0.01*
     Dementia vs MCI 0.60 (0.47–0.77) <0.001*
     SCD vs MCI 1.06 (0.71–1.59) 0.76
Current ophthalmological treatment
     Dementia vs SCD 0.55 (0.37–0.82) 0.01*
     Dementia vs MCI 0.59 (0.46–0.76) <0.001*
     SCD vs MCI 1.08 (0.75–1.57) 0.68
Table 4. Diagnostic group differences in past ophthalmological pathologies and treatments. A Multinomial 
Logistic Regression model including age, gender and years of education as co-variates was used to analyse 
group differences in past ophthalmological pathologies and treatments. For each comparison, the first listed 
group (Dementia, MCI or SCD) acted as reference. Statistical significance was set-up at p < 0.05. AMD = age-
related macular degeneration; CI = confidence interval; MCI = mild cognitive impairment; OR = odds ratio; 
SCD = subjective cognitive decline.
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suggestive of glaucomatous pathology (n = 60), dry AMD (n = 49), retinal pigmented epithelium abnormality 
(n = 47), other maculopathies (n = 30), other neuropathies (n = 19) and wet AMD (n = 19).
After completing the study’s neuro-ophthalmological exam and OCT scan, a new ophthalmological pathol-
ogy was detected in 213 participants (12.2%) (15 (6.6%) with SCD, 73 (10.7%) with MCI and 125 (15%) with 
Dementia). No statistical differences were detected among groups after adjusting for age, gender and years of 
education. The types of new ophthalmological pathologies identified were as follows: posterior pole deformation 
due to posterior staphyloma/myopia magna (n = 56), epiretinal membrane (n = 42), retinal pigmented epithe-
lium abnormality (n = 27), dry AMC (n = 23), other maculopathies (n = 13), image suggestive of glaucomatous 
pathology (n = 12) and wet AMD (n = 10). Those participants in whom a new pathology was detected were rec-
ommended to consult with an ophthalmologist for a full evaluation.
Discussion
In the present study we analyzed visual function, ophthalmologic pathologies and care received and OCT scan 
findings in a cohort of 1746 individuals evaluated at a Memory Clinic. We detected that patients living with 
Dementia presented with worse visual acuity, were less likely to receive adequate visual health care and exhibited 
suboptimal OCT scan image quality compared to those with MCI and SCD.
First, we examined the prevalence of common age-related ocular pathologies in the three study groups. After 
adjusting for age, gender and years of education, we did not detect a higher prevalence of open-angle glaucoma 
or AMD in patients with Dementia compared to those with SCD and MCI. These two ocular pathologies are 
leading causes of visual loss in older adults of developed countries and share with AD common risk factors, a 
chronic decline of function and histopathologic features, although their relationship with dementia is not fully 
understood59–62. Several studies have detected a two-to-three fold increase of glaucoma prevalence in patients 
with AD59,63 but there are conflicting results about whether patients with glaucoma have a higher risk of devel-
oping AD61,64. Most of the studies that analyze the relationship of retinal thickness changes assessed by OCT and 
cognitive decline consistently exclude cases with a previous diagnosis of open-angle glaucoma or AMD, as retinal 
thinning has been reported in these entities and could interfere with the measurement of that associated with AD 
neurodegeneration itself. It is important to note that in our cohort, as opposed to other studies, the Dementia 
group was not only comprised of AD patients (79.23%) but it also included patients with a diagnosis of Vascular 
Dementia, DLB or FTD, among others. The relation of non-AD dementia types with glaucoma is relatively under-
studied compared to AD and there is little data about glaucoma prevalence among those disorders. Also, our 
control group consisted of individuals with SCD who consulted for cognitive problems at the Memory Clinic or 
Open House Initiative program, instead of healthy subjects from the general population. Although individuals 
with SCD show unimpaired performance on formal neuropsychological testing, there is increasing evidence that 
SCD may represent the first symptomatic manifestation of AD45.
OR (95% CI) p
Reduced visual acuity:
     Dementia vs SCD 3.36 (1.77–6.39) <0.001*
     Dementia vs MCI 1.61 (1.24–2.10) <0.001*
     SCD vs MCI 0.48 (0.25–0.90) 0.02*
High Intraocular pressure:
     Dementia vs SCD 0.85 (0.40–1.83) 0.68
     Dementia vs MCI 1.08 (0.69–1.70) 0.73
     SCD vs MCI 1.27 (0.61–2.62) 0.52
Suboptimal OCT image quality:
     Dementia vs SCD 14.95 (2.01–111.03) 0.01*
     Dementia vs MCI 2.01 (1.36–2.98) <0.001*
     SCD vs MCI 0.14 (0.02–1.00) 0.05
Abnormal OCT findings:
     Dementia vs SCD 1.23 (0.67–2.25) 0.51
     Dementia vs MCI 0.81 (0.61–1.07) 0.13
     SCD vs MCI 0.66 (0.36–1.18) 0.16
Newly detected ophthalmological pathologies:
     Dementia vs MCI 1.23 (0.64–2.38) 0.54
     Dementia vs SCD 1.07 (0.77–1.50) 0.69
     SCD vs MCI 0.87 (0.46–1.66) 0.67
Table 5. Diagnostic group differences in ophthalmological exam and OCT findings. A Multinomial Logistic 
Regression model including age, gender and years of education as co-variates was used to analyse group 
differences in ophthalmological exam and OCT scan findings. For each comparison, the first listed group 
acted as the reference one. Statistical significance was set-up at p < 0.05. CI = confidence interval; MCI = mild 
cognitive impairment; OCT = optical coherence tomography; OR = odds ratio; SCD = subjective cognitive 
decline.
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Further analysis uncovered that patients with Dementia were less likely to receive ophthalmologic health care 
than their peers with SCD and MCI: despite being significantly older, they were less likely to use corrective lenses, 
received fewer ophthalmological treatments and had lower rates of ocular surgery. Of note, unadjusted data 
suggested that rates of surgeries increased parallel to the degree of cognitive impairment (SCD: 25.8% vs MCI: 
40.4% vs Dementia: 47.2%), but after accounting for age, gender and years of education, the analysis revealed 
that Dementia patients had in fact undergone fewer surgeries compared to the MCI and SCD groups. Cataract 
extraction was the most frequent ocular surgery performed in our sample (>89%) and it is known that it can 
often correct refractive errors. We acknowledge that this fact could have some impact in our data about the use 
of corrective lenses. Overall, these data suggest that despite the high prevalence of visual impairment in elderly 
patients with dementia, it is diagnosed or treated less often than in people without dementia65. As health care is 
universal and free of cost in Spain, this fact mainly excludes economic reasons for the differences detected among 
groups. One possible explanation could be the communication difficulties that patients with dementia experience 
as their cognition worsens, making them less able to report or ask support for their visual deficits. Regarding this 
issue, in Spain there are no specific guidelines for the ophthalmological evaluation and treatment of people with 
dementia. Studies show that most patients with dementia residing in long-term care facilities do not regularly 
use their prescription glasses, or those are no longer accurate28. In general, as dementia progresses, caregivers 
tend to adopt a non-invasive attitude about patients’ healthcare, to avoid surgical procedures and to seek less 
medical consultations not directly related to dementia, especially in those patients with more advanced stages of 
the disease and baseline psychotic symptoms66. In specific comorbidities, such as sensory deficits, this is known 
to be counter-productive, as the association of visual impairment and dementia in elderly population leads to 
poor quality of life, anxiety67, isolation68 and increased mortality rate69. Lastly, the phenomenon of “diagnostic 
overshadowing” could be affecting the visual care received by patients with dementia70. This term refers to the 
tendency of clinicians to overlook and underdiagnose medical co-morbidities in patients with mental retardation, 
psychiatric illnesses and dementia.
In the ophthalmological exam performed to the study participants, we detected that almost 40% of Dementia 
patients presented low visual acuity despite wearing their habitual correction for refractive errors. Visual acuity 
worsened in parallel to cognitive decline, as patients with Dementia were 3.4 and 1.6 times more likely to present 
worse visual acuity than those with SCD and MCI, respectively. Interestingly, this was not associated with previ-
ously diagnosed ocular pathologies or abnormal OCT findings. In our cohort, patients with Dementia were less 
likely to wear corrective lenses, to take ophthalmologic treatments and to undergo ocular surgery, as discussed 
above, and this could be influencing their visual acuity. Besides, complex visual deficits associated to parietal 
and occipital cortices damage that occur in AD20,22, such as impairment of reading abilities, could interfere with 
their performance in the ETDRS chart. Several studies have detected an inverse association between cognitive 
decline and visual acuity71–73. Recently, the Salisbury Eye Evaluation Study reported that visual impairment meas-
ured by the ETDRS chart was inversely associated with cognitive function quantified by MMSE scores both 
cross-sectionally and longitudinally in a large population-based sample of older US adults without dementia at 
baseline73. The Prevalence of Visual Impairment in Dementia (PrOVIDe) study is a large cross-sectional research 
project in the United Kingdom among 700 patients with dementia aged 60–89 years that reported a prevalence 
of visual impairment of 16.3% (as defined by standard logMAR < 6/18) or 32.5% (logMAR < 6/12) while partic-
ipants were using their habitual visual correction. 45% of cases of visual impairment were correctable with new 
glasses, and almost 50% of the remaining cases were associated with cataracts (and thus potentially remediable). 
Moreover, undercorrected/uncorrected visual impairment was higher in residents of nursing homes compared to 
those living in the community. 22% of participants reported not having had a sight test in the previous two years 
(including 19 participants that had not been tested in the last ten years). 16% of participants could not read stand-
ard newspaper-size print with their current visual correction. The study, though, found no evidence of differences 
in management of visual impairment in people with dementia compared to elderly population in general4.
OCT image quality was also inversely related to the degree of cognitive decline. These data are in agreement 
with our group’s recent study29 which quantified peripapillary RNFL thickness in 930 individuals including cog-
nitively healthy, amnestic-type MCI74 and AD, and showed that OCT image quality was the most influential 
factor determining RNFL variability, while there were no significant differences in RNFL thickness among clinical 
groups. Although OCT scan is considered a non-invasive and fast test, its completion requires minimum coop-
eration. Patients with moderate/advanced stages of Dementia are less able to follow directions and remain still, 
thus affecting the image quality achieved. This result may have relevant implications for OCT studies in aging and 
dementia, and suggests that data correction for image quality should be implemented in OCT studies.
Finally, we assessed OCT scan pathologic findings and newly detected ophthalmologic pathologies and found 
that there were no significant differences among groups. Unexpectedly, posterior pole deformation due to pos-
terior staphyloma/myopia magna was the most frequent OCT-based diagnosis detected in our cohort (n = 70). 
There are several factors that could explain it. First, we did not systematically record myopia magna or alterations 
in the eyeball shape as a diagnosis in the participant’s past ophthalmological history. Secondly, we only recorded 
the main OCT-based diagnosis, and given the great deformation of the posterior pole that this condition implies, 
it tends to cancel out other possible diagnoses, such as epiretinal membrane or AMD. Lastly, cases with major 
posterior pole alterations that do not fall within other more specific categories would also be included in this 
group. Among the 70 participants in which posterior pole deformation was detected, 37 of them had low visual 
acuity and 59 were using visual correction. Additionally, it is important to emphasize that a clinical diagnosis 
of glaucoma would require a face-to-face visit with an ophthalmologist, supported by functional type tests (e.g. 
visual fields evaluation), examination of the eye fundus by indirect ophthalmoscopy and/or stereoscopic pictures, 
and often several longitudinal visits to reach a firm diagnosis. Given the design of the study, we could only estab-
lish a suspicion of glaucoma, but not determine if it was primary open-angle glaucoma or a secondary glaucoma. 
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We cannot rule out that if we had performed such additional tests, the number of glaucoma diagnoses would have 
been higher in our cohort.
The main strengths of our study are the large sample size, the consensus-based clinical diagnosis and the 
double-blind nature of the study. Our study had also several limitations. First of all, we did not perform a thor-
ough ophthalmological testing covering the assessment of eye movements, reading speed or color vision, features 
that are known to be abnormal among patients with dementia. Diabetes status and review of signs of diabetes 
retinopathy were also not recorded. Furthermore, the distribution of cognitive stages within our Dementia group 
does not reflect the reality of the Memory Clinic or the general population, as patients with advanced stages of 
dementia (GDS32 > 6) were excluded from the study as they were not able to cooperate in the ophthalmologic 
exam and OCT scan. Thus, our study consists of a convenience sample instead of a pure observational/ecological 
one. On the other hand, this makes the study results even stronger, as even though our Dementia group included 
mostly mild and moderate cases, we were still able to uncover significant differences compared to MCI and SCD 
groups. Another limitation of the study is that we did not have access to private medical records and in some cases 
we may have missed relevant clinical information. Additionally, we did not perform a follow-up of those cases 
in which we detected abnormal OCT scan findings and were recommended to consult with an ophthalmologist.
To conclude, our study showed that in a large cohort of elderly individuals evaluated due to cognitive decline 
in a Memory Clinic, those diagnosed with Dementia, compared to their peers with SCD and MCI, presented 
with worse visual function, were less likely to receive visual healthcare and had suboptimal OCT image quality, 
independently of their age, gender and years of education. Both visual impairment and cognitive decline are 
major health issues in older adults that have significant adverse effects in their quality of life and threaten the 
sustainability of public health care systems. Thus, efforts should be made to guarantee regular ophthalmological 
assessments and optimize visual function in elderly patients living with dementia in order to improve their quality 
of life, avoid isolation and reduce their caregivers’ burden.
Data Availability
The datasets generated and/or analyzed during the current study are available from the corresponding author on 
reasonable request.
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